Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma
Nature Communications2014Vol. 5(1), pp. 5694–5694
Citations Over TimeTop 1% of 2014 papers
Georgina V. Long, Carina Fung, Alexander M. Menzies, Gulietta M. Pupo, Matteo S. Carlino, Jessica Hyman, Hamideh Shahheydari, Varsha Tembe, John F. Thompson, Robyn P.M. Saw, Julie R. Howle, Nicholas K. Hayward, Peter A. Johansson, Richard A. Scolyer, Richard Kefford, Helen Rizos
Related Papers
- → Combination Treatment of Patients with BRAF-Mutant Melanoma: A New Standard of Care(2017)65 cited
- → Dabrafenib in combination with trametinib for the treatment of metastatic melanoma(2014)10 cited
- → Overcoming Resistance in a BRAF V600e–Mutant Adenocarcinoma of the Lung(2018)8 cited
- → The Molecular Biology and Treatment of Malignant Melanoma with BRAFV600 Mutations(2014)1 cited
- → Vemurafenib vs. Combination Dabrafenib/Trametinib(2014)